Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Scientific News Td Cowen Raises Boston Scientific Corporation Bsx Target To $115, Reaffirms ‘buy’ Rating Ahead Of Q4 Results is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Analyst Visit Confirms Growth Potential for Boston Scientific Corporation (BSX), Buy Rating Retained
Boston Scientific Corporation (NYSE:BSX) ranks among the best medical device stocks to invest in. Following an analyst visit to Boston Scientific Corporation (NYSE:BSX)’s headquarters, TD Cowen ... Read More
Canaccord Genuity Reiterates a Buy on Boston Scientific Corporation (BSX)
Boston Scientific Corporation (NYSE:BSX) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 23, William Plovanic from Canaccord Genuity reiterated a Buy rating on Boston ... Read More
Is Boston Scientific (BSX) Becoming the Leading MedTech Growth Story?
Boston Scientific Corp. (NYSE: BSX) is one of the best stocks to buy according to Citadel LLC. On October 22, Josh Jennings, an analyst at TD Cowen, reiterated his $115 price target and Buy rating on ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus